beluuga.ai
JA
Try the Live Demo →
Overview
Wholesale Trade

cliniphar Ltd.

Cliniphar is a healthcare IT company that operates BtoB EC platforms for pharmaceutical distribution in Japan and internationally. Its domestic platform 'Kosei Market' enables medical institutions to purchase and sell prescription pharmaceuticals online, while 'synapse' is a patented database of Japanese-manufactured prescription drugs targeting overseas buyers in over 50 countries. The group leverages its subsidiary Kosei Pharma Co., Ltd., founded in 1952, to drive innovation in pharmaceutical supply chains through IT.

Market Cap
¥—B
EV
¥—B
Stock¥1,450
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
—
LTM EV/EBIT
—
LTM PER
—
LTM PBR
—
No price data
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
3.59US$22.9M'25/33.70US$23.6M'26/3
Net Income 5Y (¥B)
0.19US$1.21M'25/30.16US$1.03M'26/3
Shareholders
Top 10 hold 100.0%
as of 2026-03-31 · Source: Annual Securities Report
1
Kohei TODA
96.57%
2
Saori TODA
3.40%
3
Yuji MORISHITA
0.03%
Management
6 officers
Kohei TODA
Representative Director, President
Apr. 2000: Joined Mitsunari Yakuhin Co., Ltd. Jan. 2017: Founded Healthtech Co., Ltd. (now the Company); appointed Representative Director & President (current). May 2018: Appointed Representative Director & President of Mitsunari Yakuhin Co., Ltd. (current). Nov. 2019: Founded third eye Co., Ltd. (now Kamuna Co., Ltd.); appointed Representative Director (current).
1976-07-23
Saori TODA
Director, Executive Vice President & Head of Corporate Strategy Unit
Dec. 2013: Appointed Director of Mitsunari Yakuhin Co., Ltd. May 2016: Appointed Managing Director of the same company. Jun. 2018: Appointed Executive Vice President & Director of the same company (current). Mar. 2021: Appointed Executive Vice President & Director of the Company (current). Jan. 2025: Appointed Head of Corporate Strategy Unit of the Company (current).
1973-08-14
Shigeru KOSHIMITSU
Director, Senior Managing Executive Officer & Head of Financial Management Unit
Apr. 1982: Joined Midori Juji Co., Ltd. (now Mitsubishi Tanabe Pharma Corporation). Oct. 2014: Joined Senju Pharmaceutical Co., Ltd.; appointed General Manager, International Business Administration. Oct. 2018: Appointed Executive Officer & Head of International Business Division at the same company. May 2022: Joined the Company; appointed Executive Officer. May 2024: Appointed Director & Senior Managing Executive Officer of the Company (current). Jan. 2025: Appointed Head of Financial Management Unit of the Company (current).
1959-07-09
Daiki NAGAI
Director & Executive Officer
Apr. 1992: Joined Kobayashi Pharmaceutical Co., Ltd. Oct. 2002: Joined Kosel Co., Ltd. (now Mitsunari Yakuhin Co., Ltd.). May 2024: Appointed Director & Executive Officer of the Company (current); appointed Executive Officer of Mitsunari Yakuhin Co., Ltd. (current); appointed Head of Domestic Pharmaceutical Unit (current) and Head of Pharmaceutical Procurement Unit.
1969-01-22
Naoki SAEKI
Outside Director (Non-Executive)
Jul. 1994: Established Saeki CPA & Tax Accountant Office; appointed Director (current). Jul. 2011: Appointed Representative Member & CEO of Shikoku Matsuyama Rin Audit Corporation (current). Jun. 2019: Appointed Outside Audit & Supervisory Board Member of Takubo Engineering Co., Ltd. (current). Jul. 2020: Appointed Outside Audit & Supervisory Board Member of Mitsunari Yakuhin Co., Ltd. May 2024: Appointed Outside Director of the Company (current).
1954-01-07
Takashi TANABE
Outside Audit & Supervisory Board Member (Non-Executive)
Apr. 1978: Joined Midori Juji Co., Ltd. (now Mitsubishi Tanabe Pharma Corporation). Oct. 2002: Appointed General Manager, Accounting Department at Mitsubishi Wellpharma Co., Ltd. (now Mitsubishi Tanabe Pharma Corporation). Jul. 2004: Appointed General Manager, Accounting Department & Head of Accounting Operations Center at the same company. Oct. 2007: Appointed General Manager, Internal Controls Promotion Department at the same company (now Mitsubishi Tanabe Pharma Corporation). Oct. 2008: Appointed General Manager, Audit Department at the same company. May 2024: Appointed Outside Audit & Supervisory Board Member of the Company (current).
1951-04-14
Large Shareholding Reports
No filings
Disclosures
No disclosures
Primary Source Filings
TDnet
2026-06-25
発行者情報
FY ending Mar 2026
View PDF →
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →